Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.
Level II
Where this comes from
- Record sourced from PubMed, PMID 8229034.
- Also identified by PMC identifier 489824.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.
Medical subject headings
- Methotrexate
- Multiple Sclerosis